Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Pharmacogenet Genomics. 2010 Nov;20(11):665–676. doi: 10.1097/FPC.0b013e32833f2cd0

Table 5.

Haplotype analysis across the LD block within SLC16A7.

Haplotype rs2706301 rs10877333* rs2711655* rs12718000 rs3763980* rs10784000 Haplotype Frequency. Case,Control Frequencies Chi Square P Value
1 G T G G A A 0.28 0.36, 0.22 5.8 0.01
2 C T A G T G 0.28 0.27,0.28 0.03 0.86
3 G G A G T A 0.18 0.12,0.22 4.5 0.03
4 C T A G T A 0.12 0.11,0.14 0.49 0.48
5 G T G A T A 0.09 0.1,0.09 0.09 0.77
6 G T G G T A 0.04 0.03,0.04 0.39 0.53
*

significantly associated SNPs (p<0.05); Haplotype 1 = ‘risk’ haplotype (associated with increased risk of non-response to MTX), and Haplotype 3 = ‘protective’ haplotype (associated with a good response to MTX).